Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AAV
MCID: ANC002
MIFTS: 36

Anca-Associated Vasculitis (AAV)

Categories: Bone diseases, Cardiovascular diseases, Immune diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Anca-Associated Vasculitis

About this section

MalaCards integrated aliases for Anca-Associated Vasculitis:

IMPROVED
Name: Anca-Associated Vasculitis 19 58 75
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 19 58 71
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis 19 58 33
Aav 19 58
Anca - [antineutrophil Cytoplasmic Antibodies] Associated Vasculitis 33

Characteristics:


Prevelance:

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: 1-9/100000 (United States) 1-5/10000 (United States) 58

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases Cardiovascular diseases Respiratory diseases Bone diseases
See all MalaCards categories (disease lists)
ICD11: 33
Orphanet: 58  
Rare circulatory system diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases


External Ids:

MESH via Orphanet 44 D056648
UMLS via Orphanet 72 C2717865
Orphanet 58 ORPHA156152
UMLS 71 C2717865
Sources

Summaries for Anca-Associated Vasculitis

About this section

GARD: 19 Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of diseases (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), characterized by destruction and inflammation of small vessels. The clinical signs vary and affect several organs, such as the kidney, stomach, intestine, and lung. Skin lesions, such as purpura and urticaria, result when blood from small vessels leaks under the skin. AAV occurs when neutrophils attack small and medium vessels of the body. The underlying reason for this remains unclear.

MalaCards based summary: Anca-Associated Vasculitis, also known as anti-neutrophil cytoplasmic antibody-associated vasculitis, is related to vasculitis and granulomatosis with polyangiitis. An important gene associated with Anca-Associated Vasculitis is PRTN3 (Proteinase 3). The drugs Povidone K30 and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, monocytes and lung.

Wikipedia: 75 Anti-neutrophil cytoplasmic antibodies (ANCAs) are a group of autoantibodies, mainly of the IgG type,... more...
Sources

Related Diseases for Anca-Associated Vasculitis

About this section

Diseases related to Anca-Associated Vasculitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 907)
# Related Disease Score Top Affiliating Genes
1 vasculitis 11.5
2 granulomatosis with polyangiitis 11.5
3 polyarteritis nodosa 11.2
4 microscopic polyangiitis 11.2
5 churg-strauss syndrome 11.0
6 glomerulonephritis 11.0
7 autoimmune disease 10.9
8 end stage renal disease 10.9
9 crescentic glomerulonephritis 10.8
10 systemic lupus erythematosus 10.7
11 rapidly progressive glomerulonephritis 10.6
12 primary agammaglobulinemia 10.6
13 acute kidney failure 10.6
14 periodic fever, familial, autosomal dominant 10.6
15 interstitial lung disease 10.6
16 diffuse alveolar hemorrhage 10.6
17 lupus erythematosus 10.6
18 goodpasture syndrome 10.6
19 purpura 10.6
20 pulmonary fibrosis 10.6
21 hemophilia b 10.6
22 otitis media 10.6
23 systemic scleroderma 10.6
24 muscular dystrophy 10.6
25 lung disease 10.6
26 retinal disease 10.5
27 scleroderma, familial progressive 10.5
28 systemic lupus erythematosus 1 10.5
29 exanthem 10.5
30 pauci-immune glomerulonephritis 10.5
31 thrombophilia due to thrombin defect 10.5
32 tatton-brown-rahman syndrome 10.5
33 severe acute respiratory syndrome 10.5
34 peripheral retinal degeneration 10.5
35 retinal degeneration 10.5
36 interstitial lung disease 2 10.5
37 bell's palsy 10.5
38 muscular dystrophy, duchenne type 10.4
39 vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome 10.4
40 covid-19 10.4
41 respiratory failure 10.4
42 chronic kidney disease 10.4
43 retinitis pigmentosa 10.4
44 retinitis 10.4
45 lysosomal acid lipase deficiency 10.4
46 temporal arteritis 10.4
47 graves disease 1 10.4
48 henoch-schoenlein purpura 10.4
49 pneumocystosis 10.4
50 connective tissue disease 10.4

Graphical network of the top 20 diseases related to Anca-Associated Vasculitis:



Diseases related to Anca-Associated Vasculitis
Sources

Symptoms & Phenotypes for Anca-Associated Vasculitis

About this section
Sources

Drugs & Therapeutics for Anca-Associated Vasculitis

About this section

Drugs for Anca-Associated Vasculitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Povidone K30 Approved, Experimental Phase 4 9003-39-8 6917 131751496
2
Hydroxychloroquine Approved Phase 4 118-42-3 3652
3
Azathioprine Approved Phase 4 446-86-6 2265
4 Anti-Infective Agents Phase 4
5 Antimalarials Phase 4
6 Antiprotozoal Agents Phase 4
7 Antiparasitic Agents Phase 4
8 Antineoplastic Agents, Immunological Phase 4
9 glucocorticoids Phase 4
10 Anti-Inflammatory Agents Phase 4
11 Antineoplastic Agents, Hormonal Phase 4
12 Hormones Phase 4
13 Hormone Antagonists Phase 4
14 Tin Fluorides Phase 4
15 Antibodies Phase 4
16 Immunoglobulins Phase 4
17 Antirheumatic Agents Phase 4
18 Antimetabolites Phase 4
19 Immunosuppressive Agents Phase 4
20 Immunologic Factors Phase 4
21
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
22
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
23
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
24
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
25
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 4894 5755
26
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5 1875
27
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 4159 6741
28
Mycophenolic acid Approved, Investigational Phase 3 24280-93-1 446541
29
Clemastine Approved, Investigational Phase 3 15686-51-8 26987
30
Acetaminophen Approved Phase 3 103-90-2 1983
31
Granisetron Approved, Investigational Phase 3 109889-09-0 3510 5284566
32
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
33
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7 4897
34
Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1 33036
35 Folic Acid Antagonists Phase 3
36 Folate Phase 3
37 Vitamin B9 Phase 3
38 Vitamin B Complex Phase 3
39 Antineoplastic Agents, Alkylating Phase 2, Phase 3
40 Alkylating Agents Phase 2, Phase 3
41
Methylprednisolone Acetate Phase 2, Phase 3 584547
42 Pharmaceutical Solutions Phase 3
43 Antitubercular Agents Phase 3
44 Antibiotics, Antitubercular Phase 3
45 Anti-Bacterial Agents Phase 3
46 Gastrointestinal Agents Phase 3
47 Antiemetics Phase 3
48 Protective Agents Phase 3
49 Neuroprotective Agents Phase 3
50
Valaciclovir Approved, Investigational Phase 2 124832-27-5, 124832-26-4 60773 135398742

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
2 Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare Recruiting NCT02749292 Phase 4 Rituximab
3 Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial Recruiting NCT04316494 Phase 4 Hydroxychloroquine;Placebo
4 Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial Active, not recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
5 Prevention of Relapses in PR3-ANCA-associated Vasculitis, a Tailored Approach Terminated NCT00128895 Phase 4 azathioprine
6 Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
7 Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
8 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
9 An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis Completed NCT01697267 Phase 3 Azathioprine
10 Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
11 A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine Completed NCT02994927 Phase 3 Avacopan;Prednisone;Cyclophosphamide;Azathioprine
12 Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial Completed NCT02433522 Phase 3 rituximab;Placebo
13 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
14 A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis. Completed NCT00414128 Phase 2, Phase 3 mycophenolate mofetil;cyclophosphamide
15 Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI) Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
16 Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE) Recruiting NCT02108860 Phase 3 Abatacept;placebo
17 Evaluating Clinical and Immunological Effects of Rituximab With Cyclophosphamide Compared to Rituximab Alone in AAV Patients Recruiting NCT03942887 Phase 3 Rituximab;endoxan;Methylprednisolone;Prednisolone
18 Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial Recruiting NCT03323476 Phase 3 Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
19 Does CMV Reactivation Cause Functional Impairment of CMV Specific CD4+ T-cells? The Potential for Valaciclovir to Prevent CMV-mediated Adverse Modulation of the Immune System in Patients With ANCA-associated Vasculitis Unknown status NCT01633476 Phase 2 Valaciclovir
20 Acquired Immunodeficiency in ANCA (Antineutrophil Cytoplasmic Antibody) Associated Vasculitis Unknown status NCT03514979 Phase 2
21 Multicenter Randomized Controlled Trial Comparing Immunogenicity and Safety of Two Innovative Anti-pneumococcal Vaccine Strategies to Standard Vaccination Regimen in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy Completed NCT03069703 Phase 2 Rituximab
22 A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Completed NCT02222155 Phase 2 CCX168 low dose plus standard of care;CCX168 high dose plus standard of care
23 Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis Resistant to Conventional Therapy Completed NCT00293072 Phase 2 Rituximab
24 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Background of Cyclophosphamide or Rituximab Treatment Completed NCT01363388 Phase 2 Placebo;CCX168
25 A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase I/II Trial to Study Efficacy and Safety of Partial Substitution of Glucocorticoid for BDB-001 Injection in Patients With ANCA-associated Vasculitis Recruiting NCT05197842 Phase 1, Phase 2 BDB-001 injection;Cyclophosphamide;Glucocorticoids
26 Biologics in Refractory Vasculitis (BIOVAS): A Pragmatic, Randomised, Double-blind, Placebo-controlled, Modified-crossover Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis in Adults and Children Recruiting NCT05168475 Phase 2
27 A Randomised, Double Blind, Controlled Mechanistic Study of Rituximab and Belimumab Combination Therapy in PR3 ANCA-associated Vasculitis Active, not recruiting NCT03967925 Phase 2 Belimumab;Rituximab;Prednisolone
28 A Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Effect of Obinutuzumab Versus Rituximab in PR3-Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Not yet recruiting NCT05376319 Phase 2 Obinutuzumab;Rituximab
29 Salvage Therapy for Patients With Inadequate Response to Standard of Care Therapy in Granulomatosis With Polyangiitis Not yet recruiting NCT04871191 Phase 2 Rituximab;Tocilizumab;Abatacept
30 A Pilot Study Examining the Effect of Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
31 Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens Withdrawn NCT01275274 Phase 2 Retinoic acid;Standard of care
32 Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis Withdrawn NCT01275287 Phase 2 Standard of care treatment;eculizumab
33 Cohort Study of Chinese Patients With Pulmonary Vasculitis Unknown status NCT02126098
34 Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation Unknown status NCT02180126
35 Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis: a Pilot Study Following New Vaccine Recommendations. PneumoVas Pilot 2 Unknown status NCT02463578
36 A Qualitative Study Using Interviews With Patients Who Have Anti-neutrophil Cytoplasm Antibody (ANCA) Associated Vasculitis, to Develop a Patient Reported Outcome (PRO) Measure Unknown status NCT01729624
37 MICRO-RNAs OF NEUTROPHILS IN RENAL ANCA-ASSOCIATED VASCULITIS Completed NCT02954705
38 Patients With Co-occurrence of ANCA Vasculitis and Sjögren Syndrome : a Case Series and Systematic Review Completed NCT04895878
39 Mycophenolate Mofetil Versus Cyclophosphamide in the Induction Treatment of ANCA Associated Vasculitis Completed NCT00301652 mycophenolate mofetil
40 Observational Study of Clinical Features and Outcome of Interstitial Lung Disease With Anti-neutrophil Cytoplasmic Antibody in Chinese Patients. Completed NCT04413149
41 Tofacitinib for the Treatment of Anti-Neutrophil Cytoplasm Antibody-associated Vasculitis: a Pilot Study Completed NCT04973033 Tofacitinib
42 Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis. PneumoVas Pilot 1 Completed NCT02463539
43 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
44 Pediatric ANCA Associated-vasculitis : Latest Clinical Review and Therapeutic Outcomes. A Retrospective Epidemiological Study on a French Cohort Recruiting NCT05383573
45 The Efficacy of Leflunomide for the Maintenance Therapy of ANCA Associated Vasculitis Recruiting NCT04737343 Leflunomide;Azathioprine Tablets
46 Comparison of ANCA and Anti-GBM Auto-antibodies Removal Kinetics Between Plasma Exchanges and Immunoadsorption in Patients With ANCA-associated Vasculitis or Anti-GBM Disease Recruiting NCT03635385
47 Tailoring Maintenance Therapy to CD5+ Regulatory B Cell Recovery in ANCA Vasculitis Recruiting NCT03906227
48 PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS Recruiting NCT04664465
49 Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis Recruiting NCT03698071
50 the Application of Diffusion Tensor Imaging(DTI) in the Evaluation of Peripheral Neuropathy in Anti-neutrophil Cytoplasmic Antibodies Associated Vasculitis(AAV) Recruiting NCT04923074

Search NIH Clinical Center for Anca-Associated Vasculitis

Sources

Genetic Tests for Anca-Associated Vasculitis

About this section
Sources

Anatomical Context for Anca-Associated Vasculitis

About this section

Organs/tissues related to Anca-Associated Vasculitis:

MalaCards : Neutrophil, Monocytes, Lung, Kidney, Skin, Bone, T Cells
Sources

Publications for Anca-Associated Vasculitis

About this section

Articles related to Anca-Associated Vasculitis:

(show top 50) (show all 3384)
# Title Authors PMID Year
1
Identification of differentially expressed genes and pathways in kidney of ANCA-associated vasculitis by integrated bioinformatics analysis. 62
35172670 2022
2
Combined Electric acoustic stimulation in a patient with otitis media with antineutrophil cytoplasmic antibody-associated vasculitis. 62
33962817 2022
3
Managing ANCA-associated vasculitis during COVID-19 pandemic: a single-center cross-sectional study. 62
35918490 2022
4
What is the prognosis of ANCA-associated glomerulonephritis with immune deposition? 62
36000886 2022
5
Interstitial nephritis without glomerulonephritis in ANCA-associated vasculitis: a case series and literature review. 62
35759125 2022
6
The clinical pattern differentiates ANCA-positive infective endocarditis patients from ANCA-associated vasculitis patients: a 23 years' retrospective cohort study in China and follow-ups. 62
35906495 2022
7
How best to manage relapse and remission in ANCA-associated vasculitis. 62
36102147 2022
8
BVAS version 3 and BVAS/GPA: standing on the same line? 62
35804274 2022
9
Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review. 62
34287685 2022
10
Arterial stiffness, endothelial dysfunction and impaired fibrinolysis are pathogenic mechanisms contributing to cardiovascular risk in ANCA-associated vasculitis. 62
35998848 2022
11
The efficacy and safety of mizoribine for maintenance therapy in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis: the usefulness of serum mizoribine monitoring. 62
35908130 2022
12
Endothelium and endothelin: regulators of arterial stiffness and fibrinolysis in ANCA-associated vasculitis. 62
36272753 2022
13
Predicting bacterial infection risk in patients with ANCA-associated vasculitis in southwest China: development of a new nomogram. 62
35918562 2022
14
Intrarenal synthesis of complement C3 localized to distinct vascular compartments in ANCA-associated renal vasculitis. 62
36209693 2022
15
Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China. 62
36244021 2022
16
Immunosuppressive therapies in ear, nose and throat involvement in ANCA-associated vasculitis. Results from a multi-center retrospective cohort study. 62
36243413 2022
17
Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening. 62
36270741 2022
18
Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis. 62
36219364 2022
19
Factors influencing patient-reported outcomes in ANCA-associated vasculitis: correlates of the Patient Global Assessment. 62
35780724 2022
20
Plasma Exchange in Patients With ANCA-Associated Vasculitis: A #NephJC Editorial on a comPLEX Question. 62
36159167 2022
21
Early ultrastructural lesions of anti-neutrophil cytoplasmic antibody- versus complement-associated vasculitis. 62
35707831 2022
22
Eosinophilic Granulomatosis with Polyangiitis. 62
36259957 2022
23
Imaging characteristics of hypertrophic pachymeningitis due to ANCA-associated vasculitis. 62
35074241 2022
24
Fatigue in ANCA-associated vasculitis (AAV) and systemic sclerosis (SSc): similarities with Myalgic encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A critical review of the literature. 62
36045606 2022
25
Unclassifiable repeated antineutrophil cytoplasmic antibody (ANCA) positivity in diseases other than ANCA-associated vasculitis. 62
33904985 2022
26
New developments in treatments for systemic vasculitis. 62
35921775 2022
27
Impaired repair properties of endothelial colony-forming cells in patients with granulomatosis with polyangiitis. 62
36052734 2022
28
Off-Label Uses of Rituximab in Dermatology. 62
36217351 2022
29
Systemic lupus erythematosus and ANCA-associated vasculitis overlap syndrome. 62
36253203 2022
30
Coexistence of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and IgA nephropathy. 62
36227529 2022
31
Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management. 62
36109667 2022
32
Clinical features and management of Chinese anti-neutrophil cytoplasmic antibody-associated vasculitis patients with spontaneous renal hemorrhage: a single-center report and systematic review. 62
36190664 2022
33
Relapsing subarachnoid hemorrhage as a clinical manifestation in microscopic polyangiitis: a case report and literature review. 62
35690669 2022
34
Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. 62
34910216 2022
35
[Recommendations on the diagnosis and treatment of anti-neutrophil cytoplasmic antibody associated vasculitis in China]. 62
36207967 2022
36
Concordance between practice and published evidence in the management of ANCA-associated vasculitis in Japan: a cross-sectional web-questionnaire survey. 62
36181464 2022
37
Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature. 62
35732985 2022
38
A case of nephrogenic diabetes insipidus likely caused by anti-neutrophil cytoplastic antibody-associated vasculitis. 62
36258121 2022
39
ANCA-associated vasculitis with protein-losing enteropathy is characterized by hypocomplementemia. 62
34156527 2022
40
Monocyte-derived macrophages aggravate pulmonary vasculitis via cGAS/STING/IFN-mediated nucleic acid sensing. 62
35997679 2022
41
Clinical differences among patients with myeloperoxidase-antineutrophil cytoplasmic antibody-positive interstitial lung disease. 62
36194347 2022
42
Safety of cemiplimab for advanced cutaneous squamous cell carcinoma in a patient with p-ANCA-associated vasculitis. 62
36226470 2022
43
The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study. 62
35697489 2022
44
Chemoprophylaxis against Pneumocystis jirovecii pneumonia in Japanese patients with ANCA-associated vasculitis: an observational study. 62
36197746 2022
45
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Superimposed on Post-streptococcal Acute Glomerulonephritis. 62
35283378 2022
46
Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: the place of rituximab and plasma exchange? 62
35108368 2022
47
Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan research committee of the ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis. 62
36112482 2022
48
CD163 and CD206 expression define distinct macrophage subsets involved in active ANCA-associated glomerulonephritis. 62
36183584 2022
49
Risks and treatment related aspects of COVID-19 infection in patients with ANCA-associated vasculitis. 62
36124819 2022
50
Factors associated with cytomegalovirus infection in antineutrophil cytoplasmic antibody-associated vasculitis: A narrative review. 62
36135777 2022
Sources

Variations for Anca-Associated Vasculitis

About this section
Sources

Expression for Anca-Associated Vasculitis

About this section
Search GEO for disease gene expression data for Anca-Associated Vasculitis.
Sources

Pathways for Anca-Associated Vasculitis

About this section
Sources

GO Terms for Anca-Associated Vasculitis

About this section
Sources

Sources for Anca-Associated Vasculitis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....